Pages that link to "Q73419520"
Jump to navigation
Jump to search
The following pages link to Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) (Q73419520):
Displaying 50 items.
- Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk (Q24626884) (← links)
- Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit (Q24650533) (← links)
- Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities (Q24793111) (← links)
- Goals of statin therapy: three viewpoints (Q28214326) (← links)
- Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study (Q28287744) (← links)
- Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial (Q28351795) (← links)
- Neighborhood Socioeconomic Status in Relation to Serum Biomarkers in the Black Women's Health Study (Q28392470) (← links)
- How, when, and why to use apolipoprotein B in clinical practice (Q28645890) (← links)
- Making practical sense of clinical trial data in decreasing cardiovascular risk (Q30659167) (← links)
- Statin trials in progress: unanswered questions (Q31729029) (← links)
- Laboratory surrogates for anti-atherosclerotic drug development (Q32177501) (← links)
- Lipid Lowering Therapy to Modify Plaque Microstructures. (Q33567290) (← links)
- Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin (Q33620368) (← links)
- Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA). (Q33621905) (← links)
- Using apolipoprotein B to manage dyslipidemic patients: time for a change? (Q33820011) (← links)
- Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey (Q33972551) (← links)
- ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Pat (Q34175518) (← links)
- Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents (Q34177765) (← links)
- Use of surrogate endpoints: a practical necessity in lipid-altering and antiatherosclerosis drug development (Q34177780) (← links)
- Statin therapy: where are we? Where do we go next? (Q34188829) (← links)
- Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management (Q34188848) (← links)
- Prevention of a first myocardial infarction (Q34220548) (← links)
- Usefulness of apolipoprotein B/apolipoprotein A-I ratio to predict coronary artery disease independent of the metabolic syndrome in African Americans (Q34288900) (← links)
- Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials (Q34297213) (← links)
- Niacin or Ezetimibe for Patients with, or at Risk of Coronary Heart Disease (Q34300722) (← links)
- New developments in the prevention of atherosclerosis in patients with low high-density lipoprotein cholesterol (Q34327220) (← links)
- What are the priorities for managing cholesterol effectively? (Q34345261) (← links)
- Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading? (Q34451067) (← links)
- An equation to estimate the concentration of serum apolipoprotein B. (Q34532031) (← links)
- Both serum apolipoprotein B and the apolipoprotein B/apolipoprotein A-I ratio are associated with carotid intima-media thickness (Q34566524) (← links)
- Lipoprotein(a) Is the Best Single Marker in Assessing Unstable Angina Pectoris (Q34635132) (← links)
- The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations (Q34727571) (← links)
- Cholesterol-cholate-butterfat diet offers multi-organ dysfunction in rats (Q34911107) (← links)
- Lipoprotein heterogeneity: diagnostic and therapeutic implications (Q34990605) (← links)
- Measurement issues related to lipoprotein heterogeneity (Q34990610) (← links)
- Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity (Q34990615) (← links)
- Use of lipoprotein particle measures for assessing coronary heart disease risk post-American Heart Association/American College of Cardiology guidelines: the Multi-Ethnic Study of Atherosclerosis. (Q35007779) (← links)
- Combination therapy for combined dyslipidemia (Q35017838) (← links)
- Elevated plasma SPARC levels are associated with insulin resistance, dyslipidemia, and inflammation in gestational diabetes mellitus (Q35069694) (← links)
- Role of dietary fats in modulating cardiometabolic risk during moderate weight gain: a randomized double-blind overfeeding trial (LIPOGAIN study). (Q35070738) (← links)
- Comparison of efficacy of intensive versus mild pitavastatin therapy on lipid and inflammation biomarkers in hypertensive patients with dyslipidemia (Q35106600) (← links)
- Role of lipid and lipoprotein profiles in risk assessment and therapy. (Q35188947) (← links)
- Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment (Q35203793) (← links)
- Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety (Q35209305) (← links)
- New insights into the mechanism of low high-density lipoprotein cholesterol in obesity (Q35521069) (← links)
- NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels (Q35582273) (← links)
- Cardiovascular disease in patients who have diabetes (Q35585956) (← links)
- Impact of corpulence parameters and haemoglobin A1c on metabolic control in type 2 diabetic patients: comparison of apolipoprotein B/A-I ratio with fasting and postprandial conventional lipid ratios (Q35589699) (← links)
- Prevention of atherosclerosis by Yindan Xinnaotong capsule combined with swimming in rats (Q35607112) (← links)
- Medical lipid-regulating therapy: current evidence, ongoing trials and future developments (Q35782818) (← links)